| |
Audit
|
Nominating and Governance
|
Compensation
|
 David Scheer 
|
|
|
|
Chairman of the Board
Aegerion Pharmaceuticals
David Scheer is President of Scheer & Company, Inc., a firm founded in 1981, with activities in venture capital, corporate strategy, and transactional advisory services focused on the life sciences. Mr. Scheer was involved in the founding and had been a member of the Boards of Directors of ViroPharma, Inc.(NASDAQ, "VPHM"), OraPharma, Inc. (acquired by Johnson & Johnson in 2003), and Esperion Therapeutics, Inc. (of which he was Chairman, acquired by Pfizer in 2004). His current board relationships include Achillion Pharmaceuticals, Inc. (of which he is Chairman, NASDAQ, "ACHN"), Tengion, Inc. (of which he is Chairman, NASDAQ, "TNGN"), Aegerion Pharmaceuticals, Inc. (of which he is Chairman), Optherion, Inc. (of which he is Chairman), and Axerion Therapeutics, Inc. (of which he is Chairman). From 1991 through 1999, he was affiliated with the health care investing team at Oak Investment Partners. Mr. Scheer has also led or played a significant role in a series of transactions involving corporate alliances, licensing arrangements, divestments, acquisitions and mergers in the life sciences. He has served as a member of the Leadership Council of the Harvard School of Public Health, and as a member of the Advisory Committee to the Harvard Malaria Initiative. He has helped to launch, and currently serves as Chair of "The Unfinished Agenda in Infectious Diseases", an initiative at the Harvard School of Public Health focusing on the neglected diseases. He has also been a member of the Board of Trustees, and most recently Vice-Chair for the Long Wharf Theatre, in New Haven, CT. In 2007, he was awarded the Atlas Award for Venture Capital from the Connecticut Union for Research Excellence (CURE, of which he also serves as a member of the Board), and in 2009, he received the Venture Capital Leadership Award from the Connecticut Venture Group. He received his A.B. cum laude from Harvard College, and an M.S. from Yale University.
|
|
Sol J. Barer, Ph.D.
|
|
|
|
Celgene
Dr. Barer is the Chairman of Celgene. He previously served as Chairman and Chief Executive Officer from May 2006 until June 2010, when he was appointed Executive Chairman and transitioned to his current position in January 2011. Prior to that, he held several positions within Celgene, including President and Chief Operating Officer. Dr. Barer joined the Celanese Research Company in 1974 and formed the biotechnology group that was subsequently spun out to form Celgene. Dr. Barer also currently serves on the Board of Directors of Amicus Therapeutics, the Board of Directors of ContraFect, is Chairman of the Board of Trustees for BioNJ and Chairs the University of Medicine and Dentistry of New Jersey Advisory Committee. Dr. Barer received a Ph.D. in Organic Chemistry from Rutgers University and a B.S. from Brooklyn College.
|
|
Dr. Antonio M. Gotto, Jr., M.D., D.Ph
|
|
|
|
Weill Medical College of Cornell University
Dr. Gotto has served as a member of the board since January 2005. Dr. Gotto has been Dean of the Weill Medical College of Cornell University and Provost for Medical Affairs, Cornell University, since January 1997. He was Chairman and Professor of the Department of Medicine at Baylor College of Medicine and Methodist Hospital from 1977 through 1996 and former J. S. Abercrombie Chair, Atherosclerosis and Lipoprotein Research from 1976 to 1996. He is Past President, International Atherosclerosis Society, Past President, American Heart Association, a member of the Institute of Medicine of the National Academy of Sciences and a Fellow of the American Academy of Arts and Sciences.
|
|
Sandford ("Sandy") D. Smith
|
|
|
|
Sandy Smith joined Aegerion's Board of Directors as a member of the Audit Committee in January 2012. Mr. Smith was most recently Executive Vice President and President International Group for Genzyme Corporation (Genzyme), where he was a member of the company's Executive Committee. As President of the International Group, Mr. Smith grew Genzyme's offshore revenue to 65 percent of Genzyme's nearly $5 billion revenues. During his tenure, Mr. Smith was responsible for the successful global launch of 12 new products in various therapeutic categories, including rare diseases. Mr. Smith joined Genzyme in 1996, and served as Vice President and General Manager of Genzyme International and President of Genzyme Specialty Therapeutics before being named to his most recent position. Following Sanofi's acquisition of Genzyme in April of 2011, Mr. Smith was responsible for the integration of Genzyme's international business into the Sanofi global organization. Prior to joining Genzyme, Mr. Smith was President and Chief Executive Officer at Repligen Corporation. Under his leadership, Repligen completed several secondary stock offerings, raising more than $100 million, and established important partnerships with Merck, Eli Lilly, Gillette, and Centocor/Johnson & Johnson. He also held several international leadership positions within Bristol Myers Squibb. Mr. Smith has served as a Director on a number of boards of both public and private healthcare companies, including Ariad Pharmaceuticals, NVenta and BioBehavioral Diagnostics. He currently is a member of the Board of Trustees of Brigham and Women's Hospital in Boston.
|
|
Paul G. Thomas
|
|
|
|
Roka Bioscience
Mr. Paul G. Thomas is the Founder and CEO of Roka Bioscience, a private company developing and marketing molecular assays and instrument systems for microbiological testing. During his tenure at Roka, he led the spinout of Gen-Probe's technology assets into a new independent company with financial sponsorship from private equity firms including Orbimed Advisors, New Enterprise Associates and TPG Biotech. Prior to founding Roka Bioscience, Mr. Thomas was President, CEO and Chairman of LifeCell Corporation, a regenerative medicine company which was acquired by Kinetic Concepts in a $1.8 billion cash transaction in May 2008. Prior to that, Mr. Thomas held several positions within OHMEDA PPD (Now Baxter PPD), most recently President and Chief Operating Officer.
|
Shareholder Briefcase
Printed Materials
Email Alerts
Download Library
Snapshot
RSS News Feeds
delicious
Digg
Facebook
LinkedIn
Twitter
Yahoo! Buzz
